Shortlisted for Research Center of the Year

REMEDY has been nominated for "Center of the Year" for the first-ever "Award for Outstanding Effort in Clinical Studies."

– We are very proud that REMEDY is on the shortlist for this award, says the head of the center, Espen A. Haavardsholm

The jury has selected REMEDY from a wide range of nominees, and the center is now on a shortlist together with MATRIX, Neuro-SysMed, Oslo Myeloma Center and the Department of Oncology at Akershus University Hospital HF. The award will be presented on January 29, 2026.

– This nomination is a recognition of targeted work with clinical treatment studies within rheumatology and musculoskeletal diseases, says Haavardsholm.

– The goal is for clinical studies to be an integrated part of patient care, and this nomination gives us confirmation that we are on the right track.

This is what the jury writes about REMEDY:

REMEDY is a national and international leading research center for treatment within rheumatology and musculoskeletal diseases at Diakonhjemmet Hospital.

REMEDY was established in 2022 as one of four Research Centers for Clinical Treatment (FKB centers), with significant support from the Research Council of Norway and the Olav Thon Foundation.

The center has achieved strong growth in clinical treatment studies and is running a number of national and international multicenter studies such as HIFSAT, PICASSO, MethMax, MOVE-JIA, NOR-CACTUS, NOR-SPRINT and RA-DRUM, with high target achievement in recruitment.

Through a national clinical network, a professional trial unit, active patient council, high publication quality in leading journals and central roles in EU and Nordic projects such as the Horizon Europe study SQUEEZE, REMEDY combines strong academic quality with high relevance for patient care.

Read more about what the jury writes about REMEDY, as well as reviews of the other centers and the award